Vertex Pharmaceuticals(VRTX)

BOSTON, MABiotechnology6 H-1B visas (FY2023)

Focus: Vertex is a $9.9B revenue public biotech leader headquartered in Boston with 10,400 employees, focused on rare genetic diseases and pain. They dominate the cystic fibrosis market with KALYDECO and next-generation combination therapies.

Cystic Fibrosis Pain Sickle Cell Disease Rare Diseases

Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

10,400

Open Jobs

246+45 this month

Hot — 173 jobs added in 30d

Net +45 (173 new, 128 removed). Aggressive expansion phase.

Should You Work at Vertex Pharmaceuticals?

AI assessment

Ideal for those seeking stability in a market-leading rare-disease biotech with strong cash and hiring, but vulnerable to pipeline and market execution risk.

Why Work Here

Market-leading position in cystic fibrosis with peak-lifecycle blockbusters providing revenue stability and career longevity
Strong R&D investment ($3.2B FY2025, 32% intensity) and robust cash position ($10.5B) enabling pipeline advancement in CF, pain, sickle cell, and rare diseases

Data completeness

7/9 — Strong

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

INCIVEK

Hiring

Stable

Revenue

$9.9B

FY2025

Key Products

KALYDECO

Cystic Fibrosis CFTR Potentiator

$25M Part D

Peak7.1yr

Core revenue driver (92% of company revenue), peak-stage with patent protection through 2033; represents both strength and concentration risk.

Help build intelligence for Vertex Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Energy Balance and Weight Gain With Ivacaftor Treatment

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT02141464Energy Balance and Weight Gain With Ivacaftor Treatment

N/A

AVN944

Refractory Solid Tumors

N/A

Clinical Trials (1)

NCT00923728A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

N/A

Connected Devices for 3 months

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03304028MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique

N/A

VX-770

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT01381289VX-770 Expanded Access Program

N/A

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

N/A

Magnetic Resonance Imaging

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT04618185Gut Imaging for Function & Transit in CF - GIFT-CF 3

N/A

Ophthalmologic examinations

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT01863238An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

N/A

ivacaftor

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT02445053Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

N/A

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibros

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT02722057A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

N/A

ELX/TEZ/IVA

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT04702360ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation

N/A

ELX/TEZ/IVA

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT04058210VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

N/A

A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT04923464A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

N/A

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

DM1

N/A

Ivacaftor

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03783286Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

N/A

Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03338595Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF

N/A

telaprevir

Hepatitis C

N/A

Clinical Trials (1)

NCT00916474Virology Follow up Study in Subjects Previously Treated With Telaprevir

N/A

Rectal Biopsy

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT04254705Organoid Study R334W

N/A

Standard OGTT

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03227094Simplification of CF-related Diabetes Screening at Home

N/A

Gastrointestinal Study at Orkambi Therapy in CF Patients

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03859531Gastrointestinal Study at Orkambi Therapy in CF Patients

N/A

tezacaftor/ivacaftor

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03278314Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

N/A

Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airw

Cystic Fibrosis in Children

N/A

Clinical Trials (1)

NCT04138589Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function

N/A

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disea

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

N/A

Clinical Trials (1)

NCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

N/A

Orkambi

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03795363Orkambi Treatment in 2 to 5 Year Old Children With CF

N/A

MuCopilot mobile application

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT06147778Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis

N/A

Questionnaires

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT03659214Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults

N/A

VX-993

Pain

PHASE_1

Clinical Trials (1)

NCT06508762A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

Phase 1

VX-548

Pain

PHASE_1

Clinical Trials (1)

NCT05541471A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Phase 1

VX-121/TEZ/D-IVA

Cystic Fibrosis

PHASE_1

Clinical Trials (1)

NCT05535959A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Phase 1

VX-973

Pain

PHASE_1

Clinical Trials (1)

NCT06615570A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

Phase 1

VX-985 or matching placebo

Chronic Hepatitis C

PHASE_1

Clinical Trials (1)

NCT01144936Study of VX-985 in Subjects With Chronic Hepatitis C

Phase 1

Prednisone

Drug Interactions

PHASE_1

Clinical Trials (1)

NCT01886209Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

Phase 1

VX-634

Alpha 1-Antitrypsin Deficiency

PHASE_1

Clinical Trials (1)

NCT05579431A Phase 1, First-in-human Study of VX-634

Phase 1

telaprevir

Hepatitis C

PHASE_1

Clinical Trials (1)

NCT01038167A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Phase 1

Telaprevir

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT00933283A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Phase 1

telaprevir formulation A

Chronic Hepatitis C

PHASE_1

Clinical Trials (1)

NCT01511432A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Phase 1

VX-993

Pain

PHASE_1

Clinical Trials (1)

NCT06523595Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

Phase 1

Vanzacaftor

Cystic Fibrosis

PHASE_1

Clinical Trials (1)

NCT05867147An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Phase 1

Placebo

Pain

PHASE_1

Clinical Trials (1)

NCT05418712A Microneurography (MNG) Study of VX-150 in Healthy Participants

Phase 1

VX-548

Pain

PHASE_1

Clinical Trials (1)

NCT05560464Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Phase 1

VX-708

Acute Pain

PHASE_1

Clinical Trials (1)

NCT05347394A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Phase 1

PegInterferon

Chronic Hepatitis C

PHASE_1

lumacaftor

Cystic Fibrosis

PHASE_1

Clinical Trials (1)

NCT01899105A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Phase 1

VX-993

Pain

PHASE_1

Clinical Trials (1)

NCT06392659A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

Phase 1

MP-424

Hepatitis C

PHASE_1

Clinical Trials (1)

NCT00630058A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Phase 1

VX-809

Cystic Fibrosis

PHASE_1

Clinical Trials (1)

NCT00966602Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Phase 1

VX-509

Healthy

PHASE_1

Clinical Trials (1)

NCT00789126Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Phase 1

VCH 916

HCV Infection

PHASE_1

Clinical Trials (1)

NCT00623649Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Phase 1

ALS-002158

Hepatitis C, Chronic

PHASE_1

Clinical Trials (1)

NCT01554085First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Phase 1

VX-950

Hepatitis C

PHASE_1

Clinical Trials (1)

NCT00251199VX-950 and Peginterferon for Hepatitis C

Phase 1

Telaprevir; Moxifloxacin; Placebo

Hepatitis C

PHASE_1

Clinical Trials (1)

NCT00973388VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Phase 1

Interview Prep Quick Facts

Portfolio: 12 approved products, 148 clinical trials

Top TAs: Rare Diseases, Infectious Diseases, Nephrology

H-1B (2023): 6 approvals

Publications: 52 in PubMed

SEC Filings: 2 available

Open Roles: 246 active jobs

Portfolio Health

Pre-Launch2 (17%)

Growth2 (17%)

Peak7 (58%)

LOE Approaching1 (8%)

12 total products

Therapeutic Area Focus

Rare Diseases

8 marketed133 pipeline

45 pipeline

14 pipeline

7 marketed3 pipeline

Financials (FY2025)

Revenue

$9.9B11%

R&D Spend

$3.2B(32%)25%

Net Income

$3.6B

Hiring Trend

Actively Hiring

246

Open Roles

+48

Added

-34

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2024-08-20

46 employees affected— CA

2024-08-05

0— Bullhead City, AZ

Source: state DOL filings, aggregated via Big Local News

46 employees laid off in California closure (August 2024) plus unspecified layoffs in Arizona; suggests operational streamlining despite strong FY2025 financials.

Recent layoffs despite profitability signal pre-emptive cost management ahead of known patent cliff; expect further restructuring cycles through 2030-2031.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States.

Journal of medical economics

2026

PMID:41730016

The incidence of opioid use disorder among people with acute and chronic pain managed with prescription opioids in the United States: economic and societal burden.

Vertex Pharmaceuticals(VRTX)

Should You Work at Vertex Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (6)

Key Products by Revenue

Other Products (4)

Pipeline & Clinical Trials

Recent News · Vertex Pharmaceuticals(10)

Open Jobs (246)

Senior Director, Clinical Quality & Development Ops

Lab Automation Engineer

Senior Principal AI Engineer

Principal Full Stack AI Engineer

Principal Engineer, VaiDA User Experience

Director, Compliance Business Partner

Principal Analyst, G&A Technology

Associate Director, Patient Services Technology

Principal Analyst, PPM Technology

Program Quality Associate Director, Assurance

Senior Biostatistician II

Director, Strategic Sourcing

Health Systems Marketing Associate Director, Pain

Analytics CoE Senior Manager

Molecular & Cell Biology Senior Research Associate - Tissue Dissection

Senior Administrative Assistant

Senior Manager, RDQ Learning & Documentation Governance

Associate Director, Customer Master Lead

Associate Director, Regulatory CMC, Biologics

Director, Field Effectiveness

Patient Safety Epidemiology Associate Director

Senior Director, Commercialization Technology Architect

People Advisor, Corporate Functions

Senior Director, Finance Integration Lead

Director, Regulatory Affairs CMC

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)